Journal article

Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer

Tamar Zahavi, Mali Salmon-Divon, Roberto Salgado, Michael Elkin, Esther Hermano, Ariel M Rubinstein, Prudence A Francis, Angelo Di Leo, Giuseppe Viale, Evandro de Azambuja, Lieveke Ameye, Christos Sotiriou, Asher Salmon, Nataly Kravchenko-Balasha, Amir Sonnenblick

NPJ BREAST CANCER | NATURE RESEARCH | Published : 2021

Abstract

Heparanase promotes tumor growth in breast tumors. We now evaluated heparanase protein and gene-expression status and investigated its impact on disease-free survival in order to gain better insight into the role of heparanase in ER-positive (ER+) breast cancer prognosis and to clarify its role in cell survival following chemotherapy. Using pooled analysis of gene-expression data, we found that heparanase was associated with a worse prognosis in estrogen receptor-positive (ER+) tumors (log-rank p < 10-10) and predictive to chemotherapy resistance (interaction p = 0.0001) but not hormonal therapy (Interaction p = 0.62). These results were confirmed by analysis of data from a phase III, prospe..

View full abstract

Grants

Awarded by Clinical Research Career Development Award from the Israel Cancer Research Fund grants


Awarded by Israeli cancer research association


Funding Acknowledgements

A.S. is supported by a Clinical Research Career Development Award from the Israel Cancer Research Fund grants (16-116-CRCDA) and from the Israeli cancer research association (2017-0140). A.S. was an ESMO translational research fellow.